Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surface expression of the conserved C repeat region of streptococcal M6 protein within the Pip bacteriophage receptor of Lactococcus lactis.

Applied and environmental microbiology·2001
Same author

Studies on the genomic organization of recombinant Streptococcus gordonii and the development of a novel intergenic integration site for foreign gene expression.

Journal of molecular microbiology and biotechnology·2001
Same author

Cleavage and purification of intein fusion proteins using the Streptococcus gordonii spex system.

Preparative biochemistry & biotechnology·2001
Same author

Conserved DegP protease in gram-positive bacteria is essential for thermal and oxidative tolerance and full virulence in Streptococcus pyogenes.

Infection and immunity·2001
Same author

Identification of an intragenic integration site for foreign gene expression in recombinant Streptococcus gordonii strains.

Applied microbiology and biotechnology·2001
Same author

Oral immunization with recombinant Streptococcus gordonii expressing porphyromonas gingivalis FimA domains.

Infection and immunity·2001
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression
10:48

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression

Published on: May 15, 2014

Tecovirimat for smallpox infections.

T C Bolken1, D E Hruby

  • 1SIGA Technologies, Inc., Corvallis, OR 97333, USA.

Drugs of Today (Barcelona, Spain : 1998)
|April 16, 2010
PubMed
Summary
This summary is machine-generated.

SIGA Technologies is developing tecovirimat (ST-246) as a novel antiviral treatment for poxvirus diseases like smallpox. This drug shows promise in preclinical models and is advancing through clinical trials for public health stockpiles.

More Related Videos

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression
10:48

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression

Published on: May 15, 2014

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

  • Biotechnology
  • Virology
  • Pharmacology

Background:

  • Poxvirus-induced diseases, including smallpox (variola virus), pose significant bioterrorism threats.
  • Emerging zoonotic poxviruses like cowpox and monkeypox necessitate effective countermeasures.
  • There is a critical need for safe and effective antiviral inhibitors against poxviruses.

Purpose of the Study:

  • To advance the development of tecovirimat (ST-246) as a potential countermeasure against poxvirus infections.
  • To complete clinical trials and regulatory submissions for tecovirimat.
  • To prepare for the commercialization and supply of tecovirimat to national and global health authorities.

Main Methods:

  • Preclinical efficacy studies in small animal and nonhuman primate models for prophylaxis and therapy.
  • Phase I clinical trials and new drug application-enabling toxicology studies.
  • Phase II clinical study initiation and commercial scale-up manufacturing.

Main Results:

  • Tecovirimat (ST-246) demonstrated efficacy in all tested poxvirus disease models.
  • Phase I clinical trials and toxicology studies were successfully completed.
  • Phase II clinical study is ongoing, with manufacturing scale-up underway.

Conclusions:

  • Tecovirimat is a promising antiviral candidate for poxvirus diseases, including smallpox.
  • Clinical development and manufacturing scale-up are progressing towards regulatory approval.
  • SIGA Technologies aims to supply tecovirimat to strategic stockpiles and global health organizations.